On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) is associated with high cancer-specific mortality. While immune-checkpoint inhibitors (ICIs) improved overall survival (OS) compared to tyrosine kinase inhibitors, biomarkers predicting response to ICI in HCC are lacking. This study investigates the prognostic value of serum-based prognostic scores in patients with HCC receiving atezolizumab and bevacizumab.

Methods

This post-hoc study analysis evaluates data from the phase 3 IMbrave150 trial, comparing atezolizumab plus bevacizumab to sorafenib in patients with unresectable HCC. 212 patients were included in the analysis. The prognostic value of imaging was compared to albumin, C-reactive protein (CRP) and interleukin-6 (IL-6), as well as composite scores, including th

SUBMITTER: Hattenhauer T 

PROVIDER: S-EPMC12546374 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature